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1. Introduction
Hard tissues in human body consist of mineral phase that is
mostly composed of hydroxyapatite (HAp) and is the primary
mineral in bone and teeth.[1] However, the abnormal deposition
of calcium minerals on soft tissues known
as pathologic calcification creates the basis
of severe diseases. Calcification in soft tis-
sues leads to many extra-skeletal diseases
including calcification in hemodialysis
patients, calcific aortic stenosis, atheroscle-
rosis, kidney and bladder stones, dental
pulp stones, some gall stones, salivary gland
stones, chronic calculous prostatitis, testic-
ular microliths, some dementias, calcinosis
cutis, several malignancies, calcific tenditis,
synovitis, arthritis, and cancerous tumors.[1]
Pathological calcification is part of high
mortality diseases, such as cardiovascular
diseases with 17 million deaths per year
(reported in 2008)[2] and 42% mortality rate
in low-income and 28% in high-income
European countries (reported in 2012 and
2019)[3,4] comprising 19% of total health-
care expenditure in European countries
(recent report in 2019).[4] For example, cal-
cific aortic valve disease leads to heart fail-
ure in 50% of patients over the age of 85.[2]
Moreover, the atherosclerotic calcified pla-
ques is a highly prevalent disease, affecting about 65% of the pop-
ulation over the age of 40, where the current treatment involves
valve replacement surgeries with 3% rate of mortality.[2,5] On the
other hand, urinary tract calcification, known as kidney stones, is
a worldwide problem affecting 15% of population in developed
Dr. E. Radvar, Prof. O. Addison, Dr. S. Elsharkawy
Centre for Oral, Clinical and Translational Sciences
Faculty of Dentistry, Oral and Craniofacial Sciences
King’s College London
London SE1 1UL, UK
E-mail: sherif.elsharkawy@kcl.ac.uk
Dr. G. Griffanti, Prof. S. N. Nazhat
Department of Mining and Materials Engineering
Faculty of Engineering
McGill University
Montreal, QC H3A 0C5, Canada
The ORCID identification number(s) for the author(s) of this article
can be found under https://doi.org/10.1002/anbr.202100042.
© 2021 The Authors. Advanced NanoBiomed Research published by
Wiley-VCH GmbH. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited.
DOI: 10.1002/anbr.202100042
Dr. E. Tsolaki, Dr. S. Bertazzo
Department of Medical Physics and Biomedical Engineering
University College London




Nottingham NG7 2RD, UK
Prof. C. M. Shanahan




London SE1 1UL, UK
Physiological calcification plays an essential part in the development of the
skeleton and teeth; however, the occurrence of calcification in soft tissues such as
the brain, heart, and kidneys associates with health impacts, creating a massive
social and economic burden. The current paradigm for pathological calcification
focuses on the biological factors responsible for bone-like mineralization,
including osteoblast-like cells and proteins inducing nucleation and crystal
growth. However, the exact mechanism responsible for calcification remains
unknown. Toward this goal, this review dissects the current understanding of
structure–function relationships and physico-chemical properties of pathologic
calcification from a materials science point of view. We will discuss a range of
potential mechanisms of pathological calcification, with the purpose of identi-
fying universal mechanistic pathways that occur across multiple organs/tissues
at multiple length scales. The possible effect of extracellular components in
signaling and templating mineralization, as well as the role of intrinsically dis-
ordered proteins in calcification, is reviewed. The state-of-the-art in vitro models
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countries with a high rate of recurrence, close to 50%.[6] Despite
the presence of highly advanced clinical and surgical treatments
for calcifications such as arterial plaques and kidney stones, the
challenges for preventing the complications of stenting for ath-
erosclerosis patients and the recurrence of kidney stones drive
the scientists to offer efficient solutions.[2,5,6]
Brain calcification is vastly common in patients with neurolog-
ical or metabolic disorders, where 20% of cases are among the
elderly revealing in clinical manifestations as tremors, parkin-
sonism, seizures, and dementia.[7] The susceptibility of brain tis-
sues to calcium deposition is not clear; however, the genetic
factors seem to play an important role.[8] In brain tissue calcifi-
cations, the presence of osteogenesis markers was depicted in
calcified vasculature regions.[9] Studies on patients suffering
from Parkinson’s and Alzheimer’s diseases exhibited
α-Synuclein-positive structures.[10] Being an IDP, α-Synuclein
structures drive the attention toward the intermolecular interac-
tions of IDPs, which occur at the protein–mineral interface.[11]
The mineral characterization has provided lots of information
on the calcification process in the cardiovascular system and kid-
ney stones. Similar approaches have been applied for studying
the calcification in brain, breast cancer, and other soft tissues
over the past two decades. The opportunity that material science
offers in expanding the understanding of calcification can lead to
the emergence of more effective therapies in calcification-related
diseases.
Toward this goal, various research groups are designing mate-
rials that exhibit functionalities from disordered proteins such as
elastin[12,13] and collagen[14,15] known to be involved in pathologic
calcification.[12] This will not only allow us to study the structural
properties of those calcified tissues and pursue further mecha-
nistic understanding of the disease but also provide novel per-
sonalized and preventive treatment for those disorders. This
review aims at looking into mechanisms of calcification in path-
ologically calcified tissues (cardiovascular system, kidney, and
brain), through the intracellular and extracellular factors, to
bridge the clinical analysis into in vitro model developments
(Figure 1).
2. Phase Composition and Structural Analysis
Soft tissue calcification is a highly dynamic and complicated pro-
cess, where its structure–function relationship is not yet fully
understood.[16] On the other hand, the hierarchical structure
of the human bone and teeth tightly associates with its function,
which has been well studied.[16–18] Therefore, studying the min-
eralization pattern and structure in bones and teeth would facili-
tate our understanding of the formation and growth of calcified
deposits.[5] Furthermore, understanding the calcified lesions in
soft tissues would provide vital knowledge about the structure
of minerals formed throughout the calcification process.[19]
Figure 1. Top left: calcification in right (R), left (L) coronary and noncoronary (N) leaflet shown by three-dimensional (3D) contrast-enhanced computed
tomography (CT) reconstructions of TAVI patients. Reproduced with permission.[24] Copyright 2019, BMJ Publishing Group Ltd. Middle left: endoscopic
image of HAp deposits in renal papillae. Reproduced with permission.[56] Copyright 2013, Springer Nature; Bottom left: large calcified mass in the left
temporal lobe seen in skull X-ray. Reproduced with permission.[60] Copyright 2013, Springer Nature; scanning electron microscopy image and density-
dependent color scanning electron micrographs (DDC-SEM) of calcified cardiac tissue, kidney biopsy. Reproduced with permission.[160] Copyright 2016,
Elsevier, and brain calcification; schematic of extracellular and intracellular factors in pathological calcification (Created with BioRender.com); Top right:
prism-like mineralized structures on elastin membrane. Reproduced with permission.[12] Copyright 2018, Springer Nature. Middle right: mineralized
collagen film. Reproduced with permission.[161] Copyright 2012, American Chemical Society and Bottom right: light microscopy image of mineralized
elastin membrane. Reproduced with permission.[12] Copyright 2018, Springer Nature.
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This would further define the mechanical and functional prop-
erties of calcified tissues.[16]
2.1. Cardiovascular Calcification
Cardiovascular calcification is one of the underlying reasons for
several high-mortality diseases including atherosclerosis,[20] cal-
cific aortic valve disease,[21] and chronic kidney disease
(CKD).[22,23] Currently, there are no treatments and prevention
for cardiovascular calcification, to reverse the formation of calci-
fied deposits leading to atherosclerosis.[24,25] Even though the cal-
cified valves can be replaced by prosthetic implants, these
treatments suffer from a high death rate or implant rejection
by the host body.[26,27] One way to better understand the mecha-
nism of calcification in the cardiovascular system is to study the
structure and physico-chemical properties of the calcified depos-
its and in relation to the extracellular matrix (ECM) of the tis-
sues.[28] The multidisciplinary approach would benefit us in
analyzing these minerals using advanced imaging and spectro-
scopic techniques that are widely applied in materials science
research.
2.1.1. Composition and Nanoscale Architecture of Calcified Soft
Tissue
Applying the structural analysis approaches that are routinely uti-
lized to study the bone structure, including advanced microscopy
and spectroscopy techniques, such as scanning electron micros-
copy (SEM – nano/micrometer resolution imaging),[2,27,29] trans-
mission electron microscopy (TEM – angstrom/nanometer
resolution imaging),[2,16] selected area electron diffraction
(SAED – crystallographic structure),[2,16] and energy-dispersive
X-ray spectroscopy (EDS – elemental analysis),[2,27] would be
highly beneficial in understanding the structure–function rela-
tionship of pathological calcification.[16] Scrutinizing the compo-
sition and structural characteristics of calcified deposits provides
important information about the mechanism of calcification,
which can be compared with native bone structure.[16,19] This
is essential in finding novel treatments and techniques for pre-
venting and treating diseases that arise from pathological
calcification.
As one of the most common tissues prone to calcification, the
human aortic valve is under high risk of calcification as we
age.[16,30] Even though bioprosthetic heart valves made from por-
cine and bovine heart tissues have been used as an alternative
replacement, but they are reported to calcify over time.[31]
Structural characterization of calcified human aortic valves by
SEM showed three structural patterns, including spherical par-
ticles (Figure 2A), fibers (Figure 2B), and compact calcification
(Figure 2C) areas.[2,16] In both natural and prosthetic valves,
spherical crystalline deposits are evident, as they spread over
the surface of the tissue.[29] The crystalline structures revealed
in the calcific deposits are arranged into aggregates (1–10 μm),
large nodules (20–30 μm), and sheets that are organized along-
side the matrix fibrils in the form of fine microcrystalline needle-
like structures and aggregates.[32] Calcification in the natural
heart valve also showed spherical morphology, which covers
the surface of the tissue.[29] The spherical particles contain
calcium and phosphorus, with sizes ranging from 100 nm to
5 μm, that are not previously seen in the bone structure.[2]
They share some morphological similarities with matrix vesicles
(MVs) (membrane-bound spherical structures) to some extent,
but are not quite associated with MVs as they tend to be in large
sizes and dense structures.[2] Bertazzo et al. performed chemical
analysis on calcified aortic valves using delicate sectioning with a
focused ion beam (FIB) to examine the internal section by TEM
with EDS and SAED.[2] The analysis revealed that calcium and
phosphorus were abundant in the internal section of the calcified
lesions with a small amount of magnesium embedded therein
(Figure 2D,E).[2] The internal structure of particles composed
of concentric and unfaceted mineral layers of varying electron
density with electron diffraction patterns of highly crystalline
HAp (Figure 2F–H).[2] Even though most of the calcific lesions
show similar composition to lamellar bone composed of calcium,
phosphorus, and oxygen, but bones lack magnesium and present
a different structure.[2] The size of spherical particles can be cor-
related with the severity of the disease.[2]
2.1.2. Structure and Composition of Bone for Comparison
Bone as an impressive biological hard tissue, comprising of hier-
archical self-assembled structures that provide its stiffness and
toughness.[33] The hierarchical mineral organization of bone
mainly categorizes as longitudinal (filamentous), out of plane
(or lacy) and hexagonal structures (rosette).[33] The role of colla-
gen matrix in directing the mineral crystallization is widely
reported.[33–35]
Studying the well-established structure of bone show apatite
crystals covering the fibrillar structures of collagen (Figure 2I,J).[36]
However, the calcific lesions have been shown to be indepen-
dent from interaction with collagen fibers and rather stand
isolated and maintain their structures (Figure 2K,L).[16] In
calcified lesions, the mostly found structures are spherical par-
ticles (Figure 2K), with calcified fibers and compact calcification
depositing after spherical particles in abundance.[16] Only 13%
of the calcific lesions are reported to resemble bone structure
with lamellar bone features, and the majority are likely resulted
from dystrophic mineralization.[16] Calcific lesions do not fol-
low the nanoorganization of bone and their mineral structure
is rarely crystalline. In the analysis performed by Duer et al.,[37]
typical 13C solid-state nuclear magnetic resonance (SSNMR)
spectra revealed that the collagen signals overtake the
SSNMR spectra of bone (Figure 2M). The characteristic peaks
at 76 and 103 ppm corresponding to glycosaminoglycans
(GAGs) backbone are predominant in mineralized plaque.
2.1.3. Dystrophic and Osteogenic Calcification and Nodules
The type of calcification, being ectopic or dystrophic, depends on
the mechanical stress and proinflammatory factors. As an exam-
ple, the calcification in aortic valve is mostly dystrophic calcifica-
tion, displaying disturbed organization of elastin, lipid
depositions, chronic inflammation, fibrosis, spotted calcium
deposits, macrophage, and T-lymphocyte infiltration.[38] The cal-
cification in aortic valve leaflet presents itself in the form of nod-
ules that are rich in calcium deposits.[27] The dystrophic
www.advancedsciencenews.com www.advnanobiomedres.com
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calcification can be identified with amorphous and crystalline
deposits, in which the osteogenic calcification is present in
13% of calcified valves showing the presence of osteoid matrix
(similar to mature bone formation).[27] One method to distin-
guish the two types of calcification from each other is by scruti-
nizing the calcified nodules in the calcified tissue.[21] In the aortic
valve calcification, the hard body containing calcium phosphate
phases is named as calcified nodules observed on the fibrosa
layer of aortic valve leaflets.[27,39] In vitro models of valvular cal-
cification cleared out the differences in the dystrophic and osteo-
genic nodules that are formed in the presence of TGF-β1 and
have rather similar morphology similar to cellular aggregates
but differ in the mechanism of formation.[27] Dystrophic nodules
are more evident in dead cells, where they have a role in directing
the differentiation of aortic valve interstitial cells (AVICs) toward
myofibroblasts through inflammatory cytokines pathway.[40,41] In
contrast, osteogenic nodules are formed via osteogenesis of
AVIC-secreting bone matrix components.[21,27]
Calcified nodules are in the form of aggregates with elongated
cells in a radial pattern in dystrophic model and aggregates with
flattening cells lining along the aggregates in osteogenic
model.[27] Moreover, the size of calcified nodules is varied
depending on dystrophic or osteogenic models and are generally
larger in dystrophic nodules.[27] The calcium and phosphorus lev-
els are higher on the surface of the nodules in osteogenic com-
pared to dystrophic models, where the calcification is
Figure 2. Representative DDC-SEMmicrographs of A) calcified particles, B) calcified fibers, and C) compact calcification with a calcified particle in human
aortic valve tissue. Reproduced with permission.[16] Copyright 2016, Oxford University Press. SAED images of a calcified spherical particle (D) with its EDX
analysis (E) and compact calcification with a typical amorphous pattern (F) and its EDX analysis (G) showing that it is composed of calcium, phosphorus,
and magnesium. TEM images show spherical particles (S) trapped in compact calcium phosphate (CCP) and organic matrices (OM) (H). Reproduced
with permission.[16] Copyright 2016, Oxford University Press. Comparison of bone and heart mineralization: human woven bone: lamellar microstructure (I).
Reproduced with permission.[162] Copyright 2014, Elsevier and organization of apatite crystals and collagen fiber (J). Reproduced with permission.[36]
Copyright 2003, Elsevier; heart calcification: SEM of calcified heart valve (K). Reproduced with permission.[29] Copyright 2010, John Wiley and Sons, TEM
of compact calcification in human aortic valve calcification that collagen fibers are indicated with black arrow (L). Reproduced with permission.[16]
Copyright 2016, Oxford University Press and comparison of 13C spectra of mineralized plaque and bone (M). Reproduced with permission.[37]
Copyright 2008, Wolters Kluwer Health, Inc.
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concentrated in deeper regions of nodule.[27] This difference of
calcium and phosphorus concentrations on the surface of nod-
ules reveals information on type of calcification (dystrophic or
osteogenic), which can be used as a model to study the effective
factors in mineralization.[27,42]
The type of cells in aortic valves can play an important role in
its maintenance and function.[43] For example, valvular intersti-
tial cells (VICs) are the most abundant type and have been tar-
geted as a model for studying in vitro aortic valve calcification.[39]
The rationale behind the use of VICs as calcification models is
their trans-differentiation to bone-forming cells that mediate the
calcification process.[39] However, the environment of the VICs is
also effective in their calcification behavior. For example, a study
by Cloyd et al. confirmed the presence of TGF-β1 in osteogenic
medium may induce the collagen secretion compared to sponta-
neous deposition of calcified nodules in control medium.[39] This
observation showed that the calcification process is more con-
trolled in the osteogenic medium containing TGF-β1. In another
study, the effect of TGF-β1 is tested alongside the mechanical
strain on forming of calcified nodules,[25] which also confirmed
the increased numbers of calcified nodules with increasing con-
centrations of TGF-β1. Nevertheless, the stimulation of TGF-β1
is highly dependent on the substrate stiffness, and this should be
considered in choosing in vitro models for studying calcifica-
tion.[25] The kinetics of calcific nodule formation revealed that
the cell aggregates develop necrotic cells toward the center of
aggregate and apoptotic cells cover the ring around the periphery
of the nodule.[25]
2.1.4. Physio-Chemical Properties of Calcification
The physio-chemical process of crystal nucleation in living organ-
isms is highly regulated by cellular and extracellular mole-
cules.[15] However, studying the mineral growth phase is
essential in proposing possible mechanism of calcification.[44]
The crucial aspect in mineralization is the initiation of the nucle-
ation points, which requires the highest energy,[15] and once a
nucleus forms, the growth of crystals takes place with lower
energy levels by ion addition.[15]
The inorganic calcium orthophosphate consists of calcium,
phosphorus, and oxygen. Among the minerals phases, carbo-
nates are present as substituent anions for phosphates known
as B-type substitution, whereas smaller percentages of this sub-
stitution by magnesium increases the solubility.[45]
Biological apatite has platelet-like crystals (elongated along the
crystallographic c-axis of collagen fibrils) with small dimensions
and narrow in thickness. In contrast, the minerals in pathological
calcifications mostly occur as single or mixed phases of calcium
orthophosphates (amorphous calcium phosphate – ACP, dical-
cium phosphate dihydrate – DCPD, octa-calcium phosphate –
OCP, and β-tricalcium magnesium phosphate), magnesium
orthophosphates, calcium pyrophosphates, and calcium oxa-
lates.[45] Among all mineral phases, the most commonly reported
precursor is HAp, followed by ACP, brushite (DCPD,
CaHPO4.2H2O), monetite (dicalcium phosphate anhydrous
(DCPA), CaHPO4), and finally OCP (Ca8H2(PO4)6.5H2O).
[32]
Investigating the mineral surface and components in calcified
plaques[37] and cardiovascular deposits[46] using nuclear
magnetic resonance (NMR),[37] X-ray diffraction (XRD),[32,37,46]
and Fourier transform infrared spectroscopy (FTIR)[32,46] techni-
ques showed that the majority of initial inorganic phase of cal-
cification is a poorly crystalline carbonated apatite of B-type,
where CO3
2 partly substitutes the PO4
3 sites. Furthermore,
Ca-P phases have been identified at initial stages of mineraliza-
tion as ACP, OCP, DCPD, and magnesium-substituted β-trical-
cium phosphate.[44] Pilarczyk et al.[47] showed the growth of
calcium minerals in human aortic valves using Raman microi-
maging from the initial state of OCP-like deposits up to matura-
tion to HAp state. In EDX analysis of bioprosthetic valves,
components of calcification were detected as calcium and phos-
phorus in an atomic ratio of 1.675, and the presence of magne-
sium with a definite correlation with calcium reveals a significant
role of magnesium in calcification of valve tissue.[32] It is reported
that the magnesium occurs mostly in the early stages of calcifi-
cation in a way that stabilizes amorphous calcium phosphate in
the vesicles, where the nucleation initiates.[32]
Recognition of mineral phases is carried out either microscop-
ically due to birefringence properties of oxalate and pyrophos-
phate or by hematoxyphilia for apatite and carbonate mineral
phases.[48] Although the presence of whitlockite in medial calci-
fication of aorta being invisible to histologic methods, it is char-
acterized by XRD and EDX.[48] The formula of whitlockite,
Ca9MgH(PO4)7, that is a magnesium-substituted calcium phos-
phate, and it is referred to as β-TCP due to their similar XRD
patterns and or insolubility in acetic acid but in water.[48] In whit-
lockite, the ratio of hydrogen phosphate to phosphate is 1:6, and
Mg2þ and HPO4
2 play an important role in its structure,
whereas these two ions are absent in β-TCP.[49,50] At a maturation
state of calcification, carbonated apatite and whitlockite are
reported in human cardiovascular tissue.[51,52] Whitlockite occurs
in renal calculi with other phases of minerals such as calcium
oxalate, struvite, and apatite.[49] Analysis of crystal nucleation
and growth is beneficial in greater understanding of calcification
mechanism, which may lead to effective therapies and
treatments.
2.2. Kidney Stones
Kidney stone formation, being a complex process, can be
induced by several factors including genetic disorders, metabolic
imbalances, dietary, and lifestyle.[6,53] Analysis of the structure
and composition of kidney stones would benefit the field by
not only providing the mechanisms of mineral formation but
also the tools for advanced and effective treatments.
However, the multicomponent nature of kidney stones as mix-
tures of oxalates, phosphates, and urates is challenging for quan-
titative analysis.[54] Therefore, advanced analysis techniques are
required to be applied in kidney stone characterization.
2.2.1. Structural Characterization
Uroliths known as a condition of kidney stone formation, affect-
ing 5% of industrialized population, with two common treat-
ments; percutaneous nephrolithotripsy and extracorporeal
shockwave lithotripsy (ESWL).[55] The structural composition
of the kidney stone provides information on its mechanical
www.advancedsciencenews.com www.advnanobiomedres.com
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properties, including the hardness, which indicates the efficacy
of the ESWL treatment.[55] Better understanding of the mechani-
cal response of the kidney stones would lead to the best param-
eters for ESWL and minimizes the side effects.[55]
Smaller sizes of uroliths are called papillary renal calculi that
form 13% of renal calculi.[56] These types of renal calculi have a
concave face adjacent to the renal tissue and an opposite convex
face.[56] The concave zone can be heterogenous in the size of cal-
cified lesions, consisting from small HAp residues to Randall’s
plaques (well-developed HAp plaques) (Figure 3A1).[56,57] Two
structures are identified for the internal section of kidney stones,
including the laminar structure with no evidence of nucleus, and
the crystalline matrices that are anisotropically distributed with
either a central or peripheral nucleus.[55]
The main mineral reported in renal calculi is calcium oxalate
monohydrate (COM, CaC2O4 –H2O) along with HAp, which has
been identified in the core of the mineral. Moreover, three main
compositions are identified in kidney stones as uric acid (UA,
15%) (Figure 3A2), calcium oxalates (63–69%) (Figure 3A3),
and magnesium ammonium phosphate hexahydrate (MAPH,
10–20%).[53,55] Depending on the composition of kidney stones,
they can adopt different structures. For example, in uric
Figure 3. Types of mineralization in renal tissue (A). Typical monohydrate calcium oxalate stones harboring papillary umbilication and Randall’s plaque
made of apatite (white structures) (1), Insert: SEM of the interface between Randall’s plaque made of apatite (foreground) and stone made of mono-
hydrate calcium oxalate (background). Reproduced with permission.[57] Copyright 2019, MDPI, patient’s kidney stone samples: uric acid group with its
cross section (insert) (2) and calcium oxalate group (3). Reproduced with permission.[55] Copyright 2011, Springer Nature, SEM images of COM papillary
calculi, type IV calculus in which the core, situated near the concave zone (arrow) (4 and 5). Reproduced with permission.[56] Copyright 2013, Springer
Nature; Electron micrograph of crystal ghosts (CGs) of larger stones with concentric lamellae labeled for OPN (6 and 7), in renal calculi growth, the OPN-
containing lamellae (asterisks) are arranged concentrically around a nucleus (N) (8 and 9). Reproduced with permission.[58] Copyright 2009, John Wiley
and Sons. Pineal gland calcification (B). Backscattered electrons (BSE) images of ground surfaces of pineal concretions. Simple (1 and 2) and scallop-
shaped (3) concentric laminations around the calcospheruite center, SEM images of ground surfaces of pineal concretions showing scallop-shaped
laminations (4 and 5). Reproduced with permission.[64] Copyright 1994, Oxford University Press, calcareous concretion (HE) in the encapsulating tissue
of the pineal exhibiting the commonly observed concentric layers (6), polarization micrograph of a peripineal acervulus (unstained) showing the typical
Maltese cross (7). Reproduced with permission.[63] Copyright 1969, Springer Nature. SEM/EDX analysis of the same brain region (8), phosphorus map-
ping (9), and calcium mapping (10). Reproduced with permission.[8] Copyright 2018, Elsevier.
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acid-based samples, homogenous microstructures with
concentric laminar rings are evident.[55] On the other hand, in
the kidney stones with calcium oxalate mineral composition,
two distinct regions of globular and laminar internal structure
and white powdery external structure are common.[55] During
renal calculi formation, McKee and colleagues showed the orga-
nization of osteopontin (OPN) throughout this process.[58]
Through electron micrographs, the calculi formation is
evidenced as “crystal ghost” (CG) that immunodetecting labeling
showed the presence of OPN in concentric order around a
nucleus (Figure 3A6–9).[58]
The main difference of calcium oxalate compared to the other
composition types is its hydration ratio, which is the number of
water molecules per calcium oxalate molecule. This hydration
ratio affects the thermal decomposition of these type of stones.
In nature, calcium oxalate crystals form either as COM
(Figure 3A4,5)[56] or calcium oxalate dihydrate (COD, CaC2O4
– 2H2O), and the calcium oxalate stones contain both types in
mixed quantities.[55] Magnesium ammonium phosphate hexahy-
drate is the third common composition found in kidney stones
and often composed of a thick opaque brown outer layer with
white center.[55] The heterogeneity of the structures of uroliths
is due to the long period of time of their formation. The calcified
lesions grow larger in the collagen-rich regions and near the vasa
recta or the thin-loop basement membranes.[56]
2.2.2. Mineral Phase Composition
The morphology of kidney stones highly depends on the pH of
the environment and the growth process, where each particular
structure can be indicative of a given disease.[6] The crystal struc-
ture of the majority of minerals in kidney stones is rather mono-
clinic or orthorhombic, meaning that they have lower crystal
symmetry.[54] The appearance of kidney stones exhibits more
or less clear zonality such as, concentric layers, lamellar struc-
ture, and breccia-like structure.[54] Powder XRD and FTIR are
widely used in identifying crystalline phases, and the most
common minerals in kidney stones are whewellite (COM),
uric acid (C5H4N4O3), weddellite (COD), brushite (calcium
hydrogen phosphate dihydrate – BRS, CaHPO4·2H2O), struvite
(magnesium ammonium phosphate hexahydrate – SV,
MgNH4PO4·6H2O), HAp, carbonated HAp (CAP, Ca5(PO4,
CO3)3OH), uricite (anhydrous uric acid – UAA, C5H4N4O3), uric
acid dihydrate (UAD, C5H4N4O3·2H2O), and ammonium acid
urate (AAU, NH4C5H3N4O3).
[6,54]
Kidney stones rich in uric acid show no traces of calcium or
phosphorus in EDS spectra, and their elemental peaks consist of
C, N, and O (endothermic peak at 450).[55] On the other hand,
kidney stones rich in calcium oxalate, due to their water crystal
phases, their thermogravimetric analyses reveal three steps of
mass losses corresponding to 12% loss in the first step at
200 C, second step of mass loss at 400 C, and 26% loss of car-
bon dioxide at 740 C in the third step.[55] The EDS evaluation of
internal composition showed traces of Ca, C, and O, and the
external powdery form contains calcium phosphate due to phos-
phorus traces.[55] The MAPH decomposition is lower than the
other two, around 160 C; however, full mass loss is not achiev-
able as the calcium phosphate is resistant at higher temperatures.
Nevertheless, elemental analysis of the exterior and white inte-
rior showed that the outer layer is formed by calcium oxalate
and the interior revealed C, O, Ca, P, and Mg peaks.[55] Based
on XRD data, uroliths exhibit lower crystallinity and traces of
other minerals such as calcium oxalate dihydrate, CaCO3, and
even sodium chloride.[53] FTIR analyses of kidney stones provide
compositional data of the renal calculi structure, revealing the
vibrational stretches corresponding to specific mineral phases,
such as characteristic band of oxalate group in COM, phosphate
bands of HAp, and C─O vibration in AAU.[6] In the SEM analysis
of COM crystals, plate-like morphology randomly oriented are
more evident, whereas in stones with major composition of
UAA (98 wt%), rhomboidal blocks of uric acid crystals are
more visible.[6] Among the crystals, HAp formed the smallest
crystallite size.
2.3. Brain Calcification
Brain calcifications can occur in different regions, such as basal
ganglia, thalamus, hippocampus, and cerebellum. Calcification
is found in patients with a neurodegenerative disease, the famil-
ial idiopathic basal ganglia calcification (FIBGC) known as Fahr’s
disease that shows symmetric calcifications of the basal ganglia,
thalamus, and cerebellum.[8,59] The genetic disease of FIBGC is
based on mutations in SLC20A2 encoding inorganic phosphate
transporter (PiT2), with several studies focusing on the role of
PiT2 in this type of calcification.[59] In recent decades, the prog-
ress in imaging modalities especially cross-sectional CT make it
possible to identify intracerebral calcification.[60] Brain stones or
cerebral calculi are hard bone-like tissues that are mostly seen in
patients with seizures; they can be extra- or intra-axial in organi-
zation.[60] Imaging techniques are of great importance in finding
and diagnosing brain calcification that can be useful in under-
standing the mechanism of calcification to offer efficient
treatments.
2.3.1. Pineal Gland Calcification
Mineralization in the pineal gland is commonly observed as “cal-
cospherites,” where they can partially or fully cover the gland.[61]
It has been found in 53% of lateral skull radiographs, even
though it has been considered as a physiological phenomenon,
it also occurred in pineal tumors.[62] Early observations of dried
pineal gland with microscopes revealed that the gland conchoi-
dally fractured under pressure and mulberry-like surfaces were
exposed.[61,63] While a polarized light microscopy was used on
concretions, distorted Maltese crosses were observed,[63] indicat-
ing the presence of aggregations of several microscopic crys-
tals.[61] SEM analysis of fractured crystals showed small
needle-like crystals similar to those observed in calcified plaques
in human aortas.[61] Scanning electron analysis of pineal concre-
tions revealed two simple and scallop-shaped calcospherulite
structures (Figure 3B1–5).[64] The sectioning of the concretions
revealed flat structures, which using naphthal hydroxamic acid
(Na) staining showed the uneven scattering of calcium within
the concretions (Figure 3B6,7).[63] Microstructural analysis on
calcified region in the brain showed similar distribution of
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calcium and phosphorus in EDX mapping of calcified brain
(Figure 3B8–10).[8]
While the role of pineal gland in controlling the directional
sense is not clear, studies on patients with a lower sense of direc-
tion showed pineal gland calcification in skull radiographs.[62]
The high concentrations of magnetite found in the base of skull
around the sphenoid-ethmoid sinus complex have raised ques-
tions on the effect of magnetite on the mechanism of pineal
gland calcification.[62] Further analysis of human brain tissue
showed the presence of magnetite (Fe3O4) around the cerebral
lobes, cerebellum, basal ganglia, and midbrain.[65] The nanoscale
dimensions of these magnetite particles and prismatic crystal
shapes indicate that they are formed through biological pro-
cesses.[66] There is a correlation between the concentration of
magnetite in human brain and prevalence of Alzheimer’s disease
(AD).[66] Formation of senile plaques containing β-amyloid fibrils
as early symptoms of AD is associated with occurrence of dam-
aging reactive oxygen species through redox-active transition
metal ions.[66] The effect of magnetite is rather negative on
enhancing the toxicity of β-amyloid.[66]
2.4. Other Calcification Sites
Unlike physiological mineralization, calcification in soft tissues
can occur on undesired sites and leads to many extra-skeletal dis-
eases. We mentioned three widely studied areas in previous sec-
tions, but calcification can also occur as dental pulp stones, some
gall stones, salivary gland stones, chronic calculous prostatitis,
testicular microliths, calcinosis cutis, several malignancies, cal-
cific tenditis, synovitis, arthritis, and cancerous tumors.[1] In this
section, we briefly discuss the calcification in tendons and breast
cancer.
2.4.1. Calcific Tendonitis
Calcification in tendons, known as calcific tendonitis, is a rare
condition that little is known about its mechanism hence limited
effective therapies are available.[67] It is defined by calcium crystal
deposition (HAp) in tendons predominantly occurring in shoul-
der region with prevalence of 3% of adult population of age
between 30 and 50 years old.[68] In calcific tendonitis similarly
to other pathologic calcifications such as in cardiovascular or
renal systems, MVs are the main site of mineralization.[67,69]
The role of MVs is to provide enzymes required for regulation
of extravesicular internal tissue composition, which several stud-
ies showed that they contain necessary proteins for ion transport
across membrane including annexin V[70] and proteolipids.[71]
There are limited knowledge on the etiology of tendon calcifica-
tion, recent studies have progressed on understanding the
pathology of tendonitis.[67] In the cases that symptoms are per-
sisting, alternative treatments are investigating.
The treatment of symptomatic cases involves steroid
injection[72] or extracorporeal shockwave therapy (ESWT).[73]
However, recently, a more conservative therapeutical strategy
using a combination of nonsteroidal anti-inflammatory drugs
with physical therapy is suggesting as treatment approach.[74]
The effectiveness of these treatments decreases with severity
of calcification[73]; hence, more research is required to enhance
knowledge on the calcification mechanism to offer much effi-
cient treatments.
2.4.2. Breast Cancer
The presence of calcified deposits in tumors is commonly
reported, which 40% of breast cancer patients are presented with
microcalcification (MC) in breast tissue and is diagnosed by
mammography.[75] Breast MCs are calcium mineral deposits
in breast tissue that are an important screening tool for diagnosis
of benign or malignant breast cancer.[76] Studies showed the
morpgology of MC can be related to the aggressiveness of the
tumor, for example, casting-type MCs are reported in aggressive
tumor pathology compared to crushed stone (pleomorphic) or
powdery.[75,76] The overexpression of human epidermal growth
factor receptor type 2 (HER-2) is highly associated with the occur-
rence of MCs in premalignant breast lesions, which can be an
indicator of aggressive tumor growth.[75,77] The relationship of
MCs and breast cancer prognosis is not clear yet. The material
characterization techniques have been of great importance in
analyzing different types of MCs to expand the understanding
on its connection with breast cancer process.[78–80] Two major
types of MCs are identified in breast tissue as type I deposits con-
sist of calcium oxalate dihydrate and type II deposits contain cal-
cium phosphates, mainly HAp.[79,80] More detailed information
is reported by Haka et al. in their Raman spectroscopy analysis on
MCs in breast tissue.[80] They showed type II MCs occur in
benign lesions and contain lower levels of protein and higher
calcium carbonate content.[80] Similar to other pathological min-
eralization, mechanism pathway in breast cancer tissue leading
to MC formation is unknown, and it is most likely involves com-
plex interactions between extracellular and cellular components
with mineral moieties. Investigating possible mechanisms of cal-
cification in cardiovascular system, kidney and brain could lead
us to a more universal mineralization pathway.
3. Mechanism of Calcification
Mineralization is a physical–chemical process and in biological
systems is regulated by cells and their extracellular matrices.[15]
In chemistry, mineral deposition occurs when its solubility is
surpassed. The classical nucleation theory (CNT) states that
the crystal nucleates from elementary elements such as ions
and molecules in a supersaturated solution, where this step is
essential in crystal growth.[81] In recent years, several theories
have emerged in describing nucleation process, where CNT fol-
lows the Gibbsian concept of an energy barrier.[82] The initiation
of mineralization requires high activation energy to overcome
the energy barrier and create the prenucleation cluster.
However, this energy decreases by cells and vascular system pro-
viding high concentrations of ions for the formation of initial
crystal.[15,29] Recent findings suggesting that there is a multistage
nucleation process in contrary to CNT that are known as nonclas-
sical nucleation theories.[82] In pathological and physiological cal-
cification process, surface defects, dead cells, collagen fibrils,
elastin, lipids, and bone regulatory proteins can decrease the
energy barrier and act as nucleation sites leading to heterogenous
calcification.[29,82]
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The spreading pattern of calcified deposits within tissues is
affected by the flow of body fluid and the location of the calcifi-
cation that is susceptible to shear and compressive stresses such
as in valve openings and closings.[29] Different morphologies of
the calcified deposits within tissues have also been observed
including, spherical particles, needle-like crystals, and small/
large mineral aggregates.[32] Thermodynamically unstable Ca-P
goes through phase transformations to reach a stable
crystals phase; hence, different morphologies occur during the
calcification.[32] In vivo and in vitro calcification models differ
in their mineral deposition speed. The calcification process
in vivo results from years of accumulation of minerals due to
the presence of OPN and other regulatory factors (explained later
in this section) within the natural tissue environment acting as
inhibitors of calcification.[29] On the contrary, the mineralization
can occur only in a period of days in either elastin,[13] collagen,[14]
or synthetic in vitro models.[83] The rate of crystal formation and
thermodynamics of mineralization is widely debated area that is
discussed in recent review articles.[81,82]
Evidence shows that the biomineralization process in soft tis-
sues is a highly regulated contest between calcification promoters
and inhibitory factors; however, the exact molecular mechanism
controlling this process is not well understood.[16,44,84] One
method to understand the pathological calcification is to study
the mechanism of mineralization in natural bone and teeth. It
is evident from crystal formation in bone that the initial nucle-
ation starts from MVs that contain free cholesterol, phospholi-
pids, glycolipids, substantial quantities of phosphatidylserine
and the calcium-binding proteins annexin II and V, and deposits
of calcium and large quantities of alkaline phosphatase
(ALP).[85,86] Several studies have focused on analysis of proteins
involving in kidney stone formation, in which a number of mac-
romolecules, including OPN,[87] matrix Gla protein (MGP),[88]
bikunin[89] and Tamm-Horsfall proteins,[90] are identified in
urine and kidney stone samples (Figure 4A). However, close
to 1000 proteins have been identified in an urinary proteome
analysis that these proteins may play a vital role in crystal forma-
tion through interactions with each other.[91]
Reviewed by Abedin et al., in atherosclerotic plaques and min-
eral formation, several factors are responsible in regulating the
mineralization including bone morphogenetic protein-2 (BMP-2),
OPN, osteoprotegrin, matrix-carboxyglutamic acid protein
(MGP), and pyrophosphates, as well as smaller molecules such
as carbonates and magnesium ions.[92] On the other hand, the
loss of mineralization inhibitory factors, such as MGP and extra-
cellular inorganic pyrophosphate, is more evident in calcified tis-
sues.[93] In addition, it is also well known that there is potential
for the osteogenic differentiation of a subpopulation of primary
vascular smooth muscle cells (VSMCs) within cardiovascular tis-
sues, where the mechanisms are not yet fully understood
(Figure 4A).[92]
The role of macromolecules such as GAGs in directing the
mineralization is a highly acceptable fact in the bone; similarly,
matrix–mineral interface relationship is evident in calcified pla-
ques through a predominance of GAGs.[94,95] In calcified lesions,
the GAGs are intermixed with collagen fibrils, and as plaques
develop, the GAGs accumulate within the ECM. Moreover,
the negative effect of GAGs in calcified lesions is also their ten-
dency to bind to low-density lipoproteins that retains cholesterol,
which create proinflammatory signals.[37] Althoughmineralization-
associated proteins are not highly evident in atherosclerotic
mineral, but a clear protein–mineral interaction is yet unknown.
3.1. Matrix Vesicles
Extracellular membrane-bound structures known as MVs have
been identified as a key factor in initiating the nucleation of
HAp in physiological mineralization.[85] The MVs originate from
the plasma membrane of chondrocytes and osteoblasts.[86] Being
100 to 700 nm-sized vesicles, the mineral formed by MVs has
been observed in SEM images of aortic valve and media calcifi-
cation and in atherosclerotic lesions.[85] These vesicles contain
HAp nanocrystals that are evident in early stage of mineraliza-
tion. In contrast to spherical particles in aortic valve calcification,
the MVs are smaller in size with only 100 nm in diameter.[16]
MVs are hollow in their core and contain amorphous miner-
als.[16] In the analysis of calcification in the vessels, similar bone
tissue biomineralization processes occur and MVs have been
identified in both the tunica interna and media of the vessel
wall.[85] The formation of MVs is triggered by intercellular cal-
cium signal that results in gene transcription.[86] Although the
mechanism behind the nucleation of HAp by MVs is not well
understood, these vesicles are enriched in calcium-binding
annexins (Anx) and surface ALP, which take part in inhibiting
the activity of pyrophosphate (a HAp inhibitor factor).[86] The role
of MVs in vascular calcification has been studied by ultrastruc-
tural analysis; however, it is believed that VSMCs have a key role
in regulating the mineralization process, by going through phe-
notypic change and expression of mineralization-regulating pro-
teins.[86] The mineralization inhibitors are the reason behind
preventing calcification of VSMCs in a healthy tissue environ-
ment. The formation of MVs is observed in patients with athero-
sclerotic and CKD that were clustered with elastin and collagen
fibrils but showed no evidence of mineralization in the ECM
components.[86] What is clear in MV formation is the elevation
of extracellular calcium that triggers the VSMC response.[86,96,97]
3.2. Cellular Factors in Calcification
The concept of cellular activities in calcification mechanisms has
started to direct the researchers to the possibility of mineraliza-
tion in VSMCs.[92] Osteoclasts, large multinucleated cells, are the
cellular part that absorb the minerals in natural bone. The actin
ring around the osteoclasts provides a protease-rich, acidic
microenvironment that is required for mineral absorption.[92]
Atherosclerotic lesions being rich in monocytes and macro-
phages, which the macrophages may contribute to vascular cell
mineralization through promoting inflammatory cytokines and
producing lipid oxidation products.[92]
One technique that gives important information on formed
biominerals is solid-state NMR that has shown similarities
between the minerals in bone tissue and atherosclerotic pla-
ques.[37] Similar patterns have also been reported in the calcifi-
cation of human aortic valve resembling natural bone structure
that involves osteoblast-like cellular developments.[30] Similar to
bone, the cellular MVs have also been identified as the nucleation
sites within the atherosclerotic plaques.[86] The obvious
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difference of pathological calcification with bone mineralization
is that the HAp mineralization is well-organized and controlled
process in natural bone formation, whereas the pathological cal-
cification is rather uncontrolled.
3.2.1. Cell Phenotype
Cardiovascular calcification has been known for being a passive
process, which is driven by high concentrations of calcium and
phosphate ions within the tissues, leading to mineral deposi-
tion.[98] However, studies have revealed the important role of cel-
lular compartments in the mineralization process.[98,99] To study
this factor, Watson et al. used oxysterol 25-hydroxycholesterol
and transforming growth factor-β1 (TGF-β1), which are known
factors in atherosclerotic lesions to stimulate the calcium–
mineral nodule formation.[99] Results confirmed the effect of
25-hydroxycholesterol in increasing the nodule formation
compared to control.[99]
The evidence including the presence of bone-related proteins
and transcription factors in calcified deposits of atherosclerotic
intimal and medial areas, signifying the role of cells in vascular
wall.[30] Apart from the lineage of the cells present in vascular
walls, the transcription factors, such as Runx2/Cbfa1, Msx2,
and osterix (SP7), direct the phenotype of cells phenotype toward
Figure 4. Schematic showing the cellular factors inducing the differentiation of VSMCs to osteoblast-type cells and the ECM molecules effects on calcifi-
cation (A) (Created with BioRender.com); spherulites observed in AD hippocampal tissue stained with Congo red and haematoxylin and spherulites
notably lack affinity for hematoxylin (solid arrow-heads) shown under partially crossed polarizers (B) and same region under fully crossed polarizers (C).
Reproduced with permission.[131] Copyright 2010, IOS Press, brain tissue section (20 μm thickness) from occipital lobe stained with modified hematoxylin
and Highman’s Congo red and showing (arrow and insert) a spherulite under partially polarized light (D) crossed polarizers (E). Reproduced with
permission.[163] Copyright 2011, IOS Press, large group of spherulites of Aβ42 formed under near-physiological conditions in vitro (F) spherulite
10–12 μm in diameter with no core (F1), spherulite 15–20 μm in diameter with clear core (F2) spherulite 15–20 μm in diameter stained with Congo
red (F3). Reproduced with permission.[131] Copyright 2010, IOS Press, insulin amyloid spherulites formed without (G) and in the presence of NaCl
salt (H), spherulite size distribution (I), and ESEM images of insulin spherulites (J). Reproduced with permission.[130] Copyright 2005, Elsevier.
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osteoblast lineages.[30,98] Runx2 alone is a transcription factor
that is enough to drive the differentiation of smooth muscle cells
(SMCs) differentiation to an osteogenic lineage is Runx2.[100] In
vascular calcification, SMCs are the mostly studied cell popula-
tion, where in vitro SMC-rich cultures in media containing oste-
ogenic differentiation factors (β-glycerophosphate and l-ascorbic
acid-2-phosphate) have demonstrated enhanced calcification.[101]
This process starts from apoptosis of SMCs and is followed by
the release of extracellular vesicles (EVs) that are rich in tissue
nonspecific alkaline phosphatase (TNAP) that act as nucleator
sites.[102] Moreover, identification of cellular contribution to cal-
cification of aortic valve is rather challenging as the mineraliza-
tion capacity of VICs is unknown.[98] Some in vitro studies have
shown the growth of calcific nodules by VICs in the presence of
the cytokine-transforming growth factor-β1 through apoptotic-
dependent mechanism.[103]
3.3. Osteogenic Factors
In the 19th century, pathological studies on atherosclerotic arter-
ies revealed that the pathologic tissue resembles a bone-like
lamellar structure with osteoblast-like cells and hematopoietic
elements.[92] The key regulators in the osteogenic process are also
expressed in atherosclerotic plaques, including BMP-2,[104]
OPN,[105] MGP,[106] and osteoprotegerin (OPG).[107] The factors
that are identified in increasing the calcium build up in athero-
sclerotic plaques are modified lipid content, proinflammatory
cytokines, phosphate, lipoprotein complexes, and foci of necro-
sis.[38] Here, we look into the role of regulatory factors in soft
tissue calcification that act as either inhibitors or promoters in
osteogenic process.
3.3.1. Inhibitors
Matrix Gla Protein (MGP): MGP is a bone matrix protein that
appears in atherosclerotic plaques and artery walls, in which
the post-transitional modification of its glutamic acid residues
by carboxylation affects its function.[108] While the role of
MGP in mineralization is not well understood, studies have sug-
gested that the MGP participates in homeostatic regulatory
mechanism and limits the mineralization. Also, it has been sug-
gested that MGP’s role in regulating the mineralization is
through control of the differentiation of mesenchymal stem cells
to the osteogenic lineage by limiting production of BMP-2 thus
preventing its interaction with receptors.[109] The effect of MGP
with BMP-2 highly depending on the carboxylation of MGP and
concentrations of each molecule.[110] The factor that controls the
carboxylation of MGP is a vitamin K-dependent enzyme called
carboxylase; therefore, deficiency of vitamin K may increase
the rates of vascular calcification.[110,111]
Osteopontin: OPN is a noncollagenous matrix protein that reg-
ulates mineralization in bone and dentine as connective tissues,
but is also associated with calcifications in cardiovascular and
renal systems.[112] Looking into the polypeptide structure of
OPN, high contents of negatively charged amino acids such as
aspartate, glutamate, and serine are evident.[113] The central sec-
tion of the protein contains a highly negatively charged section
that adopts α-helical structure.[113] OPN has potential attachment
capability to different types of cells and its phosphorylated ver-
sion regulates the anchorage-dependent growth and phenotype
transformation in cells.[113] The role of OPN in bone mineraliza-
tion is thought to be on regulating the rate of crystal growth
rather than nucleating the HAp mineral. It binds to the mineral
surface via GRGDS segment and the aspartate-rich region.[113]
The inhibitory behavior of OPN during calcification is activated
through the RGD motif that binds to cells via α-v and β-3 integ-
rins.[92] It has been shown by Giachelli et al. that OPN associates
with calcified atherosclerotic plaques[114] and has a role in pre-
venting the growth of calcified crystals.[92] Another inhibitory role
of OPN may be through stimulating resorption via binding to
osteoclasts, which results in decreased cytosolic calcium.[115]
This interaction of OPN with cells is dependent on the calcium
concentration, which affects the conformation of the protein.[113]
OPN has an essential role in inhibiting calcium oxalate growth
and renal stone formation, and the pathway of inhibition is
through preventing the COM growth. The COD growth is regu-
lated by OPN, where more COD would incorporate more OSP
molecules, which is a two-way interaction.[116] COD crystals
are more readily prone to clearance with urine and they have
a lower tendency to adhere to cell surfaces.[117] This can be
the inhibitory mechanism role of OPN in HAp crystal growth.
The phosphorylation of OPN increases its mineral-regulating
effect.[116] For example, McKee and co-workers have studied
the incorporation of a serine and aspartate-rich motif, which
is present in the family of Small Integrin-Binding Ligand
N-linked Glycosylated proteins.[116] They have shown that with
an increase in negative charge and concentration of phosphory-
lated peptides, there was greater control on the crystal morphol-
ogy and elongation via binding to COD, resulting in the
formation of mushroom, dumbbell, and rosette-like crystals.[116]
The calcification mechanism of OPN is acellular and is a passive
process, although the calcification is more a cellular-mediated
process in bone and aortic valves.[112] In the renal system, the
epithelial cells showed different capacity for producing OPN
mRNA depending on the age of the kidney, where younger kid-
neys were capable of upregulating the secretion of OPN, to sup-
press the calcium oxalate crystal growth.[113]
Osteoprotegerin (OPG): OPG is a glycoprotein that regulates
bone formation, as identified by Simonet as one of the tumor
necrosis factor (TNF) receptor superfamily.[118] OPG inhibits
the later stages of osteoclast differentiation via the blocking of
RANKL, which promotes calcification in cardiac valve
myofibroblasts.[119]
Fetuin-A and Calciprotein Particles (CPPs): Fetuin-A is another
factor that plays an important role in controlling the clearance of
calcium phosphate–protein complexes called calciprotein par-
ticles (CPPs).[120] Being a glycoprotein – fetuin-A is a plasma pro-
tein that is abundant in CPPs and circulates the inhibitors of
HAp.[121] The inhibitory effect of fetuin-A is revealed through
clinical data showing lower levels of fetuin-A in urine serum
of patients suffering from calcification diseases.[38,120] Studies
on mice have shown that the fetuin-A deficiency, in addition
to calcification-prone genetic factors, is the main reason leading
to ectopic calcification.[120] This can be avoided by the supple-
mentation of calcification inhibitors including fetuin-A, pyro-
phosphate, and magnesium.[120] The effect of fetuin-A in
stabilizing the vesicle-mediating calcification is also evident in
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SMC calcification.[120] The concentration of serum fetuin-A in
urine samples of dialysis patients is reported as a predictor of
mortality leading to atherosclerosis.[121] As reported by Bilgir
et al.,[122] lower fetuin-A levels have been detected in patients
with stable angina and myocardial infarction. Due to the high
risk of intimal and medial calcification in patients with CKD,
monitoring the inhibitory factors could prevent vascular calcifi-
cations.[121] The biological activity of CPPs is based on their crys-
tallinity state, which at the ripening stage are only about
50–150 nm in diameter and are chemically unstable.[120]
Transformation of CPPs to larger size and stable state (up to
500 nm in length) is only possible in the presence of fetuin-A.[120]
Small Molecules: Inorganic Pyrophosphate: Some ubiquitous
small molecules act as mineralization inhibitors, for example,
in a study by O’Neil et al., it was shown that the administration
of pyrophosphate reduces the ectopic calcification of blood ves-
sels.[123] The ratio of phosphate–pyrophosphate is an important
factor in the development of vascular mineralization.[123] This
finding can render the pyrophosphates as promising treatment
for CKD patients.[124] The process of pyrophosphate transforma-
tion to phosphate ions is controlled by the transporter ANK
exporting through the plasma membrane, which is then
degraded by TNAP.[124] The constant removal of inhibitory pyro-
phosphate and generation of two orthophosphate ions favor the
mineralization in tissues. In using the pyrophosphate as a treat-
ment, the short half-life of this molecule should be taken into
consideration as it has a half-life of 30min in rats.[124]
Bisphosphonates: As alternative nonhydrolyzable analogs of
pyrophosphate, bisphosphonates have been used in the treat-
ment of osteoporosis in low doses, while at higher doses of
bisphosphonates have been shown to prevent vascular calcifica-
tion.[124] However, higher dosages of bisphosphonates have
adverse effects on skeletal biology and most of the nephrologists
would refrain from prescribing bisphosphonates for their CKD
patients.[124]
Magnesium: The effect of magnesium ions (Mg2þ) on the for-
mation of calcified tissues can be explained through the forma-
tion process of apatite precursors such as amorphous calcium
phosphate, dicalcium phosphate dihydrate, and octacalcium
phosphate.[125] Mg2þ ions tend to delay the rate of HAp crystalli-
zation, and this process can be explained by the blocking of min-
eralization sites on the crystal surfaces by magnesium ions.[125]
However, increased magnesium and acidic environment can
direct the whitlockite formation over HA, which in kidney whit-
lockite formation is unaffected by Mg2þ levels in the environ-
ment.[126] It can be said that the local Mg2þ concentration
determines the type of the formed mineral.
3.3.2. Promoters
Cadherin-11: Cadherin-11 (Cad-11) is considered as one of the
calcification promoter factors.[26] Cad-11 is a cell–cell adhesion
protein that plays a role in the differentiation of mesenchymal
cells to osteo- and chondrogenic lineages.[26] The expression of
Cad-11 is important in preventing inflammation and degradation
in cartilage, rheumatoid arthritis, and multiple cancer types.[26]
On the other hand, increased levels of Cad-11 expression have
been shown to promote inflammation and osteogenic
differentiation.[127] Sung et al. showed that the calcification of val-
vular myofibroblasts through the cell–cell tension and aggrega-
tion of cells can be promoted by Cad-11.[26] The signaling
pathways mediated by RhoA[26] control the Cad-11 expression,
which leads to increased stress fiber bundle, compaction and col-
lective migration, and results in calcific nodule formation.[26]
Fibulin-7: Fibulin-7 (Fbln7), which is a matricellular protein
and is structurally similar to elastogenic short fibulins, is another
promoter factor.[128] This protein has the tendency to bind to den-
tal mesenchymal cells and heparin and has been detected in
renal tubular epithelium and kidney that regulates the renal cal-
cification.[128] The expression of Fbln7 is induced by exogenous
heparin due to the N-terminal domain of Fbln7 that binds to hep-
arin through its coiled-coil domain.[128] The role of Fbln7 in cal-
cification is reported in Fbln7 knockout mice showing no
evidence of calcification. A recent study by Tsunezumi et al.
showed that Fbln7 can take part in renal tubules calcification
by directing the CPP formation in pericellular matrix using
the heparin-binding domain.[128] The Fbln7 alleviates fibrosis
and induces calcium phosphate deposition, but the Fbln7 acts
locally in calcium phosphate crystallization and the mechanism
behind this deposition is not known.[128]
3.4. Protein Regulation of Mineralization
Throughout the mineralization process, proteins can act as epi-
taxial nucleators, as well as coatings of the mineral surface, to
control the shape and size of the minerals. This process has been
studied through the binding of HAp to proteins and peptides.[15]
Mineralized tissues utilizes proteins to provide a template for
atomic-level molecular modeling.[15] In physiological calcifica-
tion of bone and enamel, it is evident that collagen and self-
assembled matrix of amelogenin nanospheres template the
nucleation and hence regulate the mineralization process,
respectively.[98,129] The fact that the majority of proteins
involved in biomineralization and HAp formation are IDPs sug-
gests that protein disorder plays a fundamental role in the
formation of protein spherulites,[12,130,131] amyloids,[132,133]
and calcification.[133]
Looking into other neurodegenerative diseases such as AD,
the spherulitic protein structures are evident with close relations
to amyloid fibrils (Figure 4).[131] Although several amyloidogenic
proteins showed spherulite structures in vitro, such as amyloid-β
in AD, α-synuclein in Parkinson’s disease, and amylin in diabe-
tes, but they have not been reported to form these structures
in vivo.
The formation of spherulites in vivo is reported for Aβ42, an
amyloidogenic peptide that is found in the core of senile plaques
in AD.[131] A study by Exley et al. showed a similar Maltese cross
pattern of amyloid spherulites in AD brain tissue with Congo red
and hematoxylin staining[131] (Figure 4F, F1–F3) that can be visu-
alized under polarized microscopy due to their birefringence
property.[134] The relation of these spherulite structures to AD
is still unknown, but the disordered proteins and their minerali-
zation can be used to shed some light on amyloid structures. A
few of amyloidogenic proteins including insulin, β-lactoglobulin,
and albumin have been shown to form spherulites under physi-
ological conditions in vitro (Figure 4G–J).[131]
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4. In vitro Models for Pathological Calcification
The successful design of scaffolds or in vitro models would ben-
efit the field in terms of understanding the calcification mecha-
nisms, by studying the interaction of minerals with the ECM
components and closely monitoring the crystal nucleation pro-
cess.[12] Understanding the rules that dictate the development
of calcified lesions across multiple tissues, while expanding from
nano- to macro- scales, is an ultimate but yet unattained goal.
Inspired by nature, natural molecules such as peptides and pro-
teins have been used in developing models for studying calcifi-
cation processes.[12,13] Toward this goal, protein’s building
blocks, amino acids with negatively charged side chains, have
been used in the design of scaffolds[135] or in the self-assembly
of polymeric hydrogels.[136] Synthetic mineralization platforms
that can emulate the features of these dynamic supramolecular
matrices, exhibiting disorder–order optimization, may lead to the
design of materials capable of recreating the structure and prop-
erties of pathological calcified tissues, as well as study their
mechanisms of formation. The generation of these in vitro mod-
els will represent a critical leap not only to elucidate the mech-
anisms of pathological calcifications but also to provide strategies
to tackle these disorders.
4.1. Polymers
Inspired by nature, several templates have been developed for
creating biomaterials with complex and sophisticated structures
mimicking their biological counterparts.[137] With the aim of fab-
ricating biomaterials with mineralization ability, natural building
blocks including peptides, proteins, polysaccharides, and lipids
are incorporated as nucleation sites, promoters, or inhibitors
of crystallization.[137] However, the use of synthetic polymers
has gained importance in biomaterials research due to their high
strength and stiffness in addition to their simple synthesis.[137]
As an example of simple synthesis, homogeneous aragonite crys-
tals are shown to form on particles of a hydrophilic triblock
copolymer, poly(diethylaminoethyl methacrylate)-b-poly(N
isopropylacrylamide)-b-poly(methacrylic acid) (PDEAEMA-
b-PNIPAM-b-PMAA), which can be synthesized in an ambient
environment and using aqueous conditions following a standard
vapor diffusion method (Figure 5).[138] In mineralization of poly-
mers, using “double hydrophilic block copolymers” can mimic
the natural mineralization in biological systems, in which the
polyelectrolyte block interacts with crystal surfaces and the other
nonionic block provides the water solubility.[138] Due to their
superior mechanical properties, synthetic polymers have been
used in the design of aortic valves. However, these polymeric
valves are prone to calcification especially on the blood-
containing polymer membrane surface.[139] Membranes fabri-
cated from polyurethanes and their copolymers were the first
generation of polymeric heart valves, which showed high rates
of calcification under fatigue tests.[140] Polyurethane valves failed
in two main ways; first, by developing holes in the central leaflet
area and second by tearing on the sides of the leaflet.[140]
Other polymers, such as polycarbonate (PCU) and polyhedral
oligomeric silsesquioxanes (POSS) nanocamposites, have also
been developed as replacement candidates for synthetic heart
valve leaflet application.[141] The POSS-PCU nanocomposite
has shown higher tensile strength compared to polyurethane-
based elastomers such as Estane®, Chronoflex C®, and
ElasteonTM (Figure 5C).[141] Despite the excellent mechanical
properties, there is a lack of long-term studies to prove the com-
patibility and calcification resistance of these nanocomposite syn-
thetic valve materials.[141] In fact, the main drawback of synthetic
polymer models is their lack of biocompatibility, which directed
research toward natural polymers in developing in vitro models.
4.2. Collagen Models
Three dimensional scaffold models are great alternatives to study
the biomechanics and changes occurring in healthy and diseased
tissues, in vitro. In designing biomaterials for mimicking the
native tissue ECM, several factors should be considered such
as, biocompatibility, cost, amenability to sterilization techniques
and easy handling. Several nature-inspired biomaterials are
designed to mimic the native mineralization processes of tissues
(Figure 5 second section).
Collagen type I, as one of the main fibrillar component in bone
ECM, has been used in the design of three-dimensional models for
mimicking bone structure.[14] In engineering a model for arterial
calcification, collagen hydrogels have been exploited to mimic
the chemical and mechanical changes of the healthy tissue through
mineralization process.[142] Farrar et al. reported an inexpensive and
versatile technique for manufacturing collagen hydrogels to mimic
the aortic valve tissue.[143] This system is compatible with live-imag-
ing techniques, and each section of the hydrogel can be sectioned
and treated for characterization accordingly. Themicroenvironment
mechanical and chemical properties strongly affect the cellular
behavior in the native tissue. For example, the biomechanics of
native aortic valve tissue is tested by designing collagen hydrogels
with controlled tension.[143] The formation of calcific nodules hard-
ens the ECM of native tissue in aortic valves and changes the VICs
phenotype that is affected by the mechanical signaling from the
ECM (Figure 6A).[143] The changes in the ECM composition influ-
ence the VIC phenotype, on the other hand, the changes in VIC’s
homeostasis result in a complex cellular feedback loop that changes
the extracellular environment.[143] Early in their studies, the increase
in TGF-β1 activity of VICs is correlated with the ascorbic acid, and
b-glycerophosphate in the osteogenic media that also induces ALP
expression in osteoblastic differentiation.[143] The calcification pro-
cess affects the ECM arrangement of VICs, disrupting the cell and
collagen fiber alignment (Figure 6B).[143]
Another advantage of using biomaterials as models for creat-
ing the calcification is to be able to closely follow the mineral
growth. As an example, the effect of collagen on mineral growth
was studied by Wang et al. revealing that the collagen fibers are
enough to initiate and orientate the growth of CHA without the
assistance of any other ECM molecules.[144] The role of EVs in
directing the vascular calcification is as yet unknown.
Hutcheson et al. developed an in vitro model of collagen-I hydro-
gel to directly observe the calcification process and contribution
of EVs to the formation of atherosclerotic plaques.[98] Their pro-
cess incubated collagen hydrogels in media containing EVs that
were collected from cultures of SMCs.[98] The formation of EVs
after three days exhibited a dense calcifying structures
www.advancedsciencenews.com www.advnanobiomedres.com
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(Figure 6C–E) resembling calcified human plaques, where their
sizes depended on changes in collagen concentration.[98] Another
example of an in vitro model of a collagen-I hydrogel to evaluate
the importance of the microenvironment, such as gel density and
anisotropy on the functionality of cells, was evaluated by Griffanti
et al.[145] An ad hoc 3D bioprinter was used to fabricate VSMC-
seeded tubular collagen bio-inks characterized by well-defined
fibrillar density and anisotropy. Interestingly, VSMCs displayed
a functional contractile state when seeded in less dense bio-inks
characterized by a randomly oriented fibrillar architecture,
whereas they did not display a contractile state when seeded
in more compact bio-inks with an anisotropic fibrillar architec-
ture.[145] This suggested that VSMC functionality can be
controlled through matrix density and architecture and may rep-
resent an interesting alternative for the study of pathological
mechanisms. In another study, the effect of HAp’s crystallinity
is examined using collagen hydrogels to mimic the human dis-
eased heart valves.[146] The severity of the disease can be corre-
lated with carbonated content and crystallinity of minerals.[146] By
varying HAp crystallinity, cellular response to mineral-rich envi-
ronment is studied by Richards et al. following a simple set up of
collagen hydrogels (Figure 6F).[146] The concentration and crys-
tallinity of HAp particles had a direct effect on the formation of
larger aggregates (Figure 6G,H), which through controlling the
concentration of incorporated HAp, different diseases severity
can be imitated.[146]
Figure 5. Higher (A) and lower (B) magnification SEM images of “sheaf bundle” crystals of hydrophilic block copolymer. Reproduced with permis-
sion.[138] Copyright 2005, John Wiley and Sons, stress–strain curves of POSS-PCU nanocomposite heart valve at 37 C (C). Reproduced with permis-
sion.[141] Copyright 2009, Elsevier. Bottom section: Transferation of pathological calcification to in vitro models: Top: structural characterization of
calcified cardiovascular tissue. From left to right: high-resolution transmission electron micrographs (HRTEM) of whitlockite particle from human aorta
tissue. Reproduced with permission.[52] Copyright 2017, Imperial College London, DDC-SEM of a large calcification within a human carotid artery plaque.
Reproduced with permission.[98] Copyright 2016, Springer Nature, SEMmicrographs of aortic calcified deposits (higher magnification – 4 μm) and (lower
magnification – 20 μm). Reproduced with permission.[5] Copyright 2001, Springer Nature, and calcified deposits in human aortic valve. Reproduced with
permission.[2] Copyright 2013, Springer Nature. Bottom row: structural characterization of in vitro models for calcification. From left to right: FIB sec-
tioning of the hierarchically mineralized structure of elastin-like recombinamers (ELR) membrane’s mineralized core (10 nm). Reproduced with permis-
sion.[12] Copyright 2018, Springer Nature, deeper within the bulk of the ELR membrane (200 nm). Reproduced with permission.[12] Copyright 2018,
Springer Nature. SEM images of elastin-like protein (ELP) membranes. Reproduced with permission.[13] Copyright 2019, American Chemical
Society. ), calcium phosphate minerals covering the peptide amphiphile/PSS hydrogel fibers (20 μm). Reproduced with permission.[83] Copyright
2019, American Chemical Society, and mineralized ELR membrane (5 cm). Reproduced with permission.[12] Copyright 2018, Springer Nature.
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4.3. Elastin Models
In arterial calcification, the ECM proteins influence where the cal-
cification occurs being either intimal or medial calcification. For
instance, intimal calcification is mostly deposited on collagen fibers,
whereas medial calcification targets the elastin as the main mineral
nucleator.[13] One approach to better comprehend the cardiovascular
calcification mechanism is using elastin as a model molecule.[13]
Elastin is reported to provide a nucleating matrix that leads to cal-
cification, as the solubilized elastin is shown by Starcher and Urry
as a potential matrix candidate for in vitro calcification.[147] Cross-
linking of elastin-like peptides created a platform to study the min-
eralization patterns in different media including simulated body
fluid (SBF)[13] and HAp [12] solutions. For example, Gourgas
et al. utilized cross-linked elastin-like peptides to develop a model
for medial arterial calcification.[13] They used genipin to cross-link
the elastin and form membranes, which showed a mineralization
pattern similar to medial calcification when incubated in SBF
(Figure 7A). The calcification starts by binding of calcium and
mostly occurs on elastin fibers, showing the vulnerability of the
fibers to mineralization.[13]
The in vitro model of elastin membranes acted in a similar
fashion to in vivo calcification of medial valve including the
occurrence of thin flake minerals of HAp in radial arrangements
after 28 days (Figure 7B,C) and 32 days of incubation
(Figure 7D).[13] The mineralized membranes showed similar dif-
fraction rings to what has been reported for native bone corre-
sponding to poorly crystalline HAp (Figure 7E,F).[13]
Moreover, these models can be a good candidate to study the
mechanical behavior of calcified tissues, as Gourgas et al. showed
that the mineralized membranes lost their initial elasticity and
get stiffer as it happens in medial calcification.[13] This change
in mechanical characterization of tissues leads to increased sys-
tolic and pulse pressure known as source of left ventricular
hypertrophy and failure, aneurysm formation, and rupture.[13]
Looking from the physicochemical and compositional side to
the mineralization of ELP3 membranes, they showed the pres-
ence of HAp and CHA that are most abundant mineral phases
in pathological calcification due to its thermodynamic stability.[13]
These membranes showed very small amount of OCP minerals
that only picked up by Ca K-Edge near edge X-ray absorption fine
structure spectroscopy (NEXAFS).[13]
Similarly, Mata’s group revealed that the interplay between
disorder (random coils) to order (β-sheets/α-helices) domains
within IDPs is critical during mineralization (Figure 7G).[12,13]
The contribution of IDPs in the intermolecular interaction at
the protein–mineral interface has been shown in amelogenin
while interacting with enamel crystals[11] as an example. The
changes from disordered to ordered conformations are believed
to be the source for mineral nucleation and growth.
Developing in vitro models that can create the optimizable
disorder–order interplaying system is a promising approach in
understanding the diseased environment. The elastin-like
recombinamers (ELRs) have been used as a model recombinant
macromolecule, due to their biocompatibility, biodegradability,
and the presence of charged amino acids, to study the
Figure 6. Mechanically active VIC hydrogels showing nodules: bright field images of hydrogels at days 1, 5, and 14 (A, arrows indicate nodules), immu-
nofluorescence of hydrogels revealing collagen fibres in white (B). Reproduced with permission.[143] Copyright 2016, Elsevier. DDC-SEM of calcifying EVs
within a synthetic collagen hydrogel (scale bars, 500 nm) (C), bright field image of collagen hydrogel indicating EVs (yellow arrow) (D), FTIR absorbance
spectra of large calcification (dark red spectrum line) and microcalcification (light blue spectrum line) (E). Reproduced with permission.[98] Copyright
2019, Springer Nature. Schematic preparing HAp-containing collagen hydrogels (F), incorporation of poorly crystalline HAp1 (G) and crystalline HAp2 (H)
particles inside the collagen hydrogels (0.25mgml1, insert is TEM image of HAp particles). Reproduced with permission.[146] Copyright 2018, Elsevier.
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mineralization process. The repeating unit of Val-Pro-Gly-X-Gly
(VPGXG), where X can be any amino acid except proline, is sim-
ilar to natural elastin and allows for it to be used as a model for
IDP.[148] In the designed ELRmodel by Elsharkawy et al., a hydro-
phobic segment of VPGIG and a positively charged segment as
VPGKG were used that the lysine is the target site for cross-
linking.[12] The cross-linked membranes (Figure 7H) mineral-
ized in highly saturated solution that resulted in spherulite-like
hierarchical structures that grow radially into circular pattern
(Figure 7I). The mineralization pattern not only covers the sur-
face but also is evident within the membrane.[12] The mineral
type was confirmed by XRD data and 19 F NMR, which are in
agreement with fluorapatite crystalline phase. Further analysis
into the crystallographic orientation of the mineralized mem-
branes performed by HRTEM on super thin sections of the
membrane (sectioned by FIB). The thin sections revealed a flat
geometry at the end of their c-axis evidencing the effect of ELR
matrix on interacting with fluorapatite crystals and providing an
environment in favor of mineral growth.[12] These membranes
can be optimized through their disorder–order ratio by control-
ling the cross-linking agent that the spherulite formation and
mineralization patterns depend on this ratio (Figure 7J).[12]
Incorporation of IDPs in the design of in vitro models can
provide us with insights into the mechanism of calcification in
soft tissues such as cardio or brain that leads to severe diseases.[12]
4.4. Other Models
Biomaterial approach as in vitro models has designed mostly tar-
geting vascular system. Here, we discuss in vitro models for
studying MVs in tendon calcification, mimicking kidney stones
and investigating breast cancer MCs.
To study the interaction of ECM components and MVs, Gohr
et al. designed an in vitro model using isolated MVs from adult
porcine patellar tendons embedded in agarose gels and investi-
gate the effect of ECM components such as type I collagen
and dermatan sulfate on the mineralization of MVs.[67] They
showed the effect of dermatan sulfate, a major proteoglycan in
tendon ECM, in suppressing the mineralization of tendon matrix
vesicle, which changes such as aging and diabetes can cause inter-
ruption in ECM components’ behavior leading to calcification of
soft tissue.[67] In another study, gelatin gels are used as in vitro
model to study the mineralization mechanism of MVs isolated
from chondrocytes culture.[149] They indicated that changes in
mineralization inhibitor such as enzymes, including adenosine
triphosphate or ECM component, proteoglycans contribute to
Figure 7. Schematic of mineralization mechanism (A), SEM images of ELP3 membranes after incubation in SBF for 24 days (B,C) and 32 days (D),
high-resolution TEM image of an ultrathin section ELP3 membranes after 32 days incubation (E), SAED image from mineral region (F). Reproduced
with permission.[13] Copyright 2019, American Chemical Society. Schematic of ELR matrix assembly and nucleation (G), photograph of a transparent,
robust, and flexible statherin-ELR membrane before mineralization (H), aligned fluorapatite nanocrystals (I), protein disorder–order optimization (Scale
bars: 3 μm (ELR spherulite morphology), 20 μm (apatite hierarchical structures) (J). Reproduced with permission.[12] Copyright 2018, Springer Nature.
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lowering the calcification of MVs.[149] The in vitro models used in
this study, gelatin, is a denatured type I collagen that can down-
grade the ionic concentrations compared to in vivo conditions.[149]
In vitro models for studying the calcification in kidney are only
limited to artificial kidney stones. These models are created to
determine the effectiveness of various testing extract or com-
pounds for treatment of urolithiasis.[150] The benefits of
in vitro models not only include preliminary studies before inva-
sive in vivo testing but also prevent high number of costly rep-
licates and animal studies.[150] Conventional 2D cell culture
models are used to inhibit the crystal-binding sites in renal epi-
thelial cells that resulted in decreased crystal aggregation.[150]
However, 2D models are not representative of more complex
in vivo conditions and does not incorporate ECM, inhibitors,
and promotors of calcification. Despite the limitations of
in vitro urolithiasis models, they can still provide great knowl-
edge on prophylactic management to prevent stone recurrence
and test effective laser treatments.[151] One of the in vitro models
used for mimicking the kidney stone formation is simultaneous
flow static model (S.S.M.) that use salt-forming solution that
dropwise is being collected in hot water then goes through crys-
tallization by cooling and drying.[150] Another model, silica-hydro
gel acts as a growth medium, which seeding solution added to
the formed gel reacts with the gel structure leading to the growth
of different types of single urinary crystals.[150] This model is
used to evaluate the crystallization of urinary crystals.
The materials science has got close to study kidney stones in the
field of artificial kidney stones that are useful in investigating the
connection between laser parameters and stone fragmentation
patterns (Figure 8).[151] Polymer-mineral composites and commonly
used BegoStone, a dry gypsum plaster, are examples of artificial
stones that seek to mimic the mechanical properties of human kid-
ney stones.[151] These artificial stones are used for extracorporeal
shockwave lithotripsy research to better optimize the holmium laser
lithotripsy treatments.[151] The composite stones are made from
COM as the primary mineral component of human kidney stone,
uric acid, magnesium ammonium phosphate hexahydrate in an
organic polymeric substrate (poly(ethylene-o-vinyl acetate))
(Figure 8B(insert) and C).[151] Even though the microstructure of
these artificial stones does not represent the human kidney stones,
they share similar physical and spectroscopic properties that can be
useful in single-pulse laser lithotripsy experiments.[151] These
in vitro models help to elucidate the response of kidney stones
to laser treatments, but still there is a big gap in understating
the mechanism of kidney stone formation. There is a great need
for developing biomaterials to create a platform to study themineral
formation with consideration of more complex in vivo environment
as an attempt to design better technologies in kidney stone manage-
ment and prevention.
To understand the connection of malignancy of breast cancer
and MCs mineral characteristics, in vitro models have been
applied.[76] Moreover, tissue-engineered scaffolds are used as
in vitro platform to study the effect of HAp particle size on
mammary cancer cell activity.[152] The mineral-containing
poly(lactide-co-glycolide) (PLG) scaffold showed that the particle
size of HAp crystals modulates protein adsorption.[152] Breast
cancer cell growth and secretion of tumorigenic interleukin-8
(IL-8) are reported to change with HAp mineral morphology
Figure 8. Other in vitro models: a crater formed from single-pulse holmium:YAG laser lithography experiment in a human COM stone (scale bar 150 μm),
multifocus image is shown on the left, and 3D reconstruction image is shown on the right (A), crater volume compared for human kidney stones and four
types of BegoStone model with decreasing ratios of mineral to water (insert showing the mechanically robust artificial kidney stone PVA composite) (B)
and crater volume graphs of composite artificial kidney stone models (red: COM mineral, green: UA mineral and blue: MAPH mineral) that the optimal
concentration of th epolymer is indicated by blue arrow (C). Reproduced with permission.[151] Copyright 2019, American Chemical Society; alginate gel
manufacturing process as summarized in (D) and cell proliferation and cluster formation are higher in softer gels reaching clusters of 100 μm in one
week (E). Reproduced with permission.[156] Copyright 2016, Springer Nature.
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and level of carbonate in the crystal, studied in a 2D mineralized
culture plate.[153] 2D in vitro models were also incorporated by
Morgan group to study the calcium deposition and ALP activity
of breast cancer cell lines with a combination of mineralizing
reagents.[154] Even though 2D culture models are suitable to
investigate the effect of a factor or reagent on cell behavior, they
have limitations in mimicking the 3D tissue microenvironment.
Development of 3Dmicrofluidic systems offer a 3D environment
with properties similar to in vivo conditions specified for an
organ.[155] Cancer metastases are simulated in a 3D tri-culture
microfluidic in vitro model with creating a osteo-cell microenvi-
ronment using collagen type I hydrogel.[155] The mechanical sup-
port of ECM is an important parameter to include in the design
of in vitro models. This has been applied in 3D alginate hydrogels
that are mechanically tuned (Figure 8).[156] The stiffness of algi-
nate hydrogels is controlled by the crosslinker CaCl2 content.
[156]
The elastic modulus (E) of hydrogels was measured by atomic
force microscopy and the effect of the elasticity of the microen-
vironment on breast adenocarcinoma cell activity.[156] The stiff-
ness of the gel affected the proliferation and cluster formation of
cells that they form nigger clusters in softer gels (Figure 8E).[156]
Several studies covered the required parameters in tissue-
engineered scaffolds for mimicking bone structure.[157,158] The
essential properties including biocompatibility, porosity, surface
properties, mechanical properties, and biodegradability[157] are
some of these parameters that most of these factors are also
important in designing in vitro models for studying pathological
calcification. However, the important factor to be considered for
in vitro models is the ability to support mineral growth. Porosity
and diffusion are essential for crystal nucleation and growth.[158]
Different strategies are reported to mimic biomineralization sys-
tems including premineralized scaffolds using SBF or HAp solu-
tion.[12] Although in vitro models are not as extensively studied
for pathological calcification as it has been for bone mineraliza-
tion, but there is a great potential in developing a platform for
studying pathological calcification in vitro. For this purpose,
materials that are inspired from nature can be suitable candi-
dates including mineralizing peptides[159] and proteins.[158]
5. Conclusion and Future Prospective
Pathological calcification is a complicated process that concerns
several soft tissues including cardiovascular, brain, and renal sys-
tems. The exact mechanism that causes the deposition of miner-
als is not fully understood. However, the structural
characterizations using high-resolution electron microscopy,
XRD, and spectroscopy techniques provide us with information
regarding the kinetics of mineralization, type, and morphology of
minerals. The structure–function relationship of bone and teeth
has been widely studied and using that as a reference would assist
us in predicting the mechanism of pathological calcification.
Cardiovascular system being vulnerable tissue for calcification
gives us a chance to study the microstructure of calcified deposits
using advanced microscopy and spectroscopy techniques. The
morphology of calcified deposits can be as spherical particles,
fibrillar, or compact surface. Moreover, the two types of dystro-
phic and osteogenic calcification lead us to look into the effect of
osteogenic factors and extracellular molecules on promoting the
calcification of soft tissues. On the other hand, the physicochem-
ical analysis of minerals being either HAp, whitlockite, or other
phases can help us in understanding the mechanism.
The mechanism of physiological calcification has demon-
strated a balance between inhibitory and promoter factors in tis-
sues such as bone. Osteogenic process takes place by the
controlled imbalance between these two factors leading to the
formation of MVs as precursors of bone minerals.
Nevertheless, there are other components affecting the mineral-
ization process being either intracellular or extracellular.
The ECM proteins such as collagen evidently act as a template
for nucleation of bone minerals, and amelogenin acts as a tem-
plate for growth of enamel nanospheres.[98,129] Protein disorder
and order assemblies play an important role in mineralization as
most of the proteins involved in calcification are from the IDP
family group. This fact can be confirmed by the formation of pro-
tein spherulites,[12,130,131] amyloids,[132,133] and calcification.[133]
Studying pathological calcification from the protein disorder
point of view can be beneficial in predicting the mechanism
through in vitro models such as designs studied with elastin
membranes[12,13] and collagen hydrogels.[144] These models offer
an opportunity to create the tissue-mimetic environment to sim-
ulate the pathological calcification to shine light on its mecha-
nism of calcification. This approach would highly benefit the
areas of pathological calcification such as brain calcification that
lack the in vitro models to assist us in understanding the mecha-
nism of mineralization. Clearly, further studies are required to
advance more complex in vitro models that incorporate IDPs and
cellular factors to eventually develop therapies and treatments for
diseases caused by pathological calcification.
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